Press Release

STADA expands Specialty rare-disease offering with tafamidis capsules

- STADA builds out its Specialty rare-disease portfolio by introducing tafamidis soft-gel capsules in several of Europe's largest pharma markets – initially in France, Germany and Spain – at the earliest possible date
- Vyndaqel reference product is currently one of Europe's best-selling medicines, with Pfizer having recorded 2025 global annual sales for the Vyndaqel product family of US$6.38 billion across all approved indications
- STADA Head of Global Development, Portfolio, Regulatory and Business Development/Licensing, Yann Brun: "Launching tafamidis for treating hereditary ATTR-CM, with limited competition, demonstrates the dedication to rare diseases that STADA has already built beyond cardiology, in areas such as nephrology"

Bad Vilbel, Germany – 24 November 2026 – STADA is building out its portfolio of Specialty rare-disease therapies by introducing tafamidis 61mg soft-gel capsules in several European countries – initially in France, Germany and Spain.

Tafamidis 61mg soft-gel capsules are indicated for treating hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTRm-CM), a rare and progressive form of heart disease characterized by the deposition of abnormal amyloid protein in the heart tissue, leading to heart failure.[1] STADA's launch follows the loss of exclusivity in the ATTRm-CM indication of the Vyndaqel reference product. Vyndaqel benefits from orphan market

[1] WHF-Policy-Summary-ATTR-CM-1.pdf

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler / Bryan Kim
Chairman of the Supervisory Board: Dr. Günter von Au

exclusivity for treatment of senile systemic amyloidosis (ATTRwt-CM) that will expire on 19 February 2030.[2]

Pfizer reported 2025 global sales of the Vyndaqel product family[3] 17% higher at $6.38 billion, including international ex-US revenues that climbed by 34% to $2.55 billion, “driven largely by strong demand with continuing uptake in patient diagnosis primarily in the US and certain international developed markets, as well as improved patient affordability in the US”.

At the same time, STADA is further strengthening its cardiovascular portfolio by rolling out the anticoagulant apixaban in multiple European countries.

STADA Head of Global Development, Portfolio, Regulatory and Business Development/Licensing, Yann Brun commented: “Launching tafamidis for treating hereditary ATTR-CM, with limited competition, demonstrates the dedication to rare diseases that STADA has already built beyond cardiology, in areas such as nephrology. It also complements our ever stronger cardiovascular offering that we are currently reinforcing through the roll-out of the anticoagulant apixaban in several countries. Bringing competition to two of Europe’s best-selling medicines promises to expand patient access without raising healthcare spending, thereby delivering on STADA’s purpose of Caring for People’s Health as a Trusted Partner.”

About STADA

STADA is headquartered in Bad Vilbel, Germany. The group focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA sells its products in over 100 countries. In financial year 2025, STADA achieved group sales of € 4,296 million. As of 31 December 2025, STADA employed 11,670 people worldwide.

[2] Union Register of medicinal products - Public health - European Commission

[3] Vyndaqel product family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the US and Vynmac in Japan.

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler / Bryan Kim
Chairman of the Supervisory Board: Dr. Günter von Au



STADA information for journalists
STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
E-Mail: press@stada.com
Or visit us via our website at https://www.stada.com/media/newsroom
Follow @StadaGroup on LinkedIn

STADA information for capital market participants
STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de
Or visit us via our website at https://www.stada.com/investor-relations/

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler / Bryan Kim
Chairman of the Supervisory Board: Dr. Günter von Au